Recent Press Releases

New Merck Headquarters Starts Taking Shape

New Merck Headquarters Starts Taking Shape - Groundbreaking for modular Innovation Center - New building in Darmstadt will further interdisciplinary and project-related collaboration to promote...

Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial

- Study showed significantly more HF-REF patients on LCZ696 regimen were alive, had fewer hospitalizations than those given enalapril regimen(1)

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

PISCATAWAY, N.J., Aug. 29, 2014 /PRNewswire/ -- InnoPharma, Inc.

Ebola vaccine trials fast-tracked by international consortium

Unprecedented international consortium -- including the University of Maryland School of Medicine and NIH -- now assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine<

Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA

Represents First BLA Submission for a PCSK9 Inhibitor

THOUSAND OAKS, Calif., Aug.

Mylan's ANDA for Three Times Per Week Generic Copaxone(R) 40 mg/mL Accepted for Filing by FDA

PITTSBURGH, Aug. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL...

More information needed on type 2 diabetes drug empagliflozin

More information needed on type 2 diabetes drug empagliflozin NICE has called for more evidence from Boehringer Ingelheim on its drug empagliflozin for treating type 2 diabetes in new draft guidance....

Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA

Momenta Pharmaceuticals MNTA, -1.92% today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a three-times-a-week...

Moberg Pharma AB (Formerly known as Moberg Derma)'s Head Of U.S. Operations To Resign By End Of January 2015

Moberg Pharma AB (Formerly known as Moberg Derma)'s Head Of U.S. Operations To Resign By End Of January 2015 STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (MOB.ST) today announced...

FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure

THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S.

Sanofi Appoints Jez Moulding to the Position of President, North America Pharmaceuticals

Sanofi Appoints Jez Moulding to the Position of President, North America Pharmaceuticals Bridgewater, N.J. – August 27, 2014 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced the...

GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive...

Allergan to Request California Federal Court Block Valeant and Pershing Square from Voting Shares Acquired in Violation of Insider Trading Laws

Announces Date for Special Meeting of Stockholders IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") announced today that it has asked...

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

New JARDIANCE Simple Savings program currently offered in doctors' offices and online

RIDGEFIELD, Conn. and

NAFTA Tribunal Decision Supports FDA and Its Actions

NAFTA Tribunal Decision Supports FDA and Its Actions TORONTO, Aug. 26, 2014 /PRNewswire/ - Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that an arbitration tribunal...

Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen

Pfizer and Merck to Collaborate on Study Evaluating Novel Anti-Cancer Combination Regimen Agreement to Combine Merck's Investigational Anti-PD-1 Antibody Pembrolizumab and Pfizer's crizotinib...

Valeant Canada acquires Valeo Pharma's portfolio

Valeant Canada acquires Valeo Pharma's portfolio The pharmaceutical company consolidates its leadership position in dermatology in Canada LAVAL, QC, Aug. 25, 2014 /CNW Telbec/ - Valeant Canada...